Archive - July 12, 2016

MARLBORO — After years of declining enrollment, a renaissance may be underway at Marlboro College. The number of new students submitting deposits for the upcoming fall term has increased by nearly 50 percent compared to last year, in part due to the success of a new “Renaissance Scholars” free tuition program aimed at drawing students from outside New England. Also, the college just finished what President Kevin Quigley (Thailand 1976-79 & CD Thailand 2013-15)  is calling the most successful annual fundraiser in its history. Marlboro raised more than $2 million, a 25 percent jump from last year’s total. While much work remains, college administrators say they’re seeing signs of progress — especially in addressing enrollment numbers that recently had dipped below 200. “From today’s vantage point, I think the future looks very good,” said Montpelier attorney Dick Saudek, chairman of the college’s board of trustees. “With any small liberal arts college, there . . .

A $750,000 study designed to examine if taking the malaria prevention drug, chloroquine (Arlen) would reduce the risk of breast cancer among RPCV women did not attract sufficient number of respondents.  It is not clear if any further study will be done.  The research team needed between 14,000 t0 18,000 participants, but less than 500 RPCV women had responded by May of 2014. The three year study ended in 2015. Background: The  Research Team at Baylor College of Medicine in Houston, Texas received the  $750,000 grant from the Department of Defense to study, “A Translational Approach to Validate In Vivo Anti-Tumor Effects of Chloroquine on Breast Cancer Risk”. Animal studies had suggested that female mammals who were given chloroquine had a lifetime reduced risk of breast cancer. The grant was awarded to Baylor to investigate if this effect could be found in human females.  The Baylor team chose to study RPCV . . .